Category Archives: Stem Cell Therapy

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--

BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI.OB - News), a developer of innovative stem cell technologies for neurodegenerative disorders, announced that NurOwn™, its autologous stem cell therapy for amyotrophic lateral sclerosis (ALS), or Lou Gehrig's Disease, was profiled yesterday on CNBC. In the Feature Story about the impact of Iran's nuclear threat, Israeli business and scientific leaders were interviewed about Israel's thriving economy and cutting edge technologies. Among those leaders that met with CNBC were Brainstorm’s President Mr. Chaim Lebovits and Prof. Dimitrios Karussis, Principal Investigator of Brainstorm's Phase I/II clinical trial currently underway at the Hadassah Medical Center in Jerusalem.

Brainstorm recently announced positive initial results from the clinical trial, resulting in approval from Hadassah's Helsinki committee to proceed with the trial. Accordingly, additional patients have been enrolled in the study, and Brainstorm will announce additional results in the coming months.

To see the video online, follow the link at: http://video.cnbc.com/gallery/?video=3000074883

To read the Feature Story online, follow the link at: http://www.cnbc.com/id/46484576

Safe Harbor Statement
Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. The potential risks and uncertainties include risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. The Company does not undertake any obligation to update forward-looking statements made by us.

Continued here:
BrainStorm Featured on CNBC

Global leader in animal stem cell technology is poised for significant expansion through new partnership with top U.S. companion animal health distribution company.

Las Vegas, Nevada (PRWEB) February 22, 2012

MediVet-America, the global leader in veterinary stem cell technology and regenerative medicine, has entered into a distribution partnership with Butler Schein Animal Health, a division of Henry Schein, the leading companion animal health distribution company in the U.S., to sell and distribute stem cell kits and equipment to veterinarians serving the nation’s fast-growing $50 billion pet industry.

The announcement was made today at the Western Veterinary Conference in Las Vegas by Jeremy Delk, CEO of MediVet-America.

The two companies will partner to sell and distribute MediVet-America’s advanced stem cell technology to more than 26,000 veterinary clinics nationwide. Adult animal stem cell technology uses the body’s own regenerative healing power to help treat dogs, cats, horses and other animals suffering from painful arthritis, hip dysplasia and tendon, ligament and cartilage injuries and other ailments.

The Adipose-Derived Stem Cell Procedure Kit and state of the art equipment, co-developed with Medical Australia, enable veterinarians to remove a small sample of fat, separate the stem cells, then activate and inject them into affected areas.

“We are pleased to be teaming up with Butler Schein, the largest companion animal health distribution company in the nation,” said Delk. “Their strong track record in sales and distribution will further fuel our rapid growth and bring this breakthrough technology to more leading veterinary practices across the country.”

To introduce the distribution partnership, Delk said MediVet-America has developed an exclusive program of product and service offers that will be made available only to Butler Schein customers.

Veterinary practitioners in more than 200 markets throughout 42 states now perform the drug-free procedure entirely in their own clinics more quickly, effectively and economically than earlier generation animal stem cell therapy. MediVet-America’s new treatment, developed in Australia, is available in 26 countries worldwide.

“This exciting partnership will allow even more of our colleagues unparalleled access to MediVet-America’s superior technology, providing the most affordable and efficacious stem cell therapy in the industry,” said Mike Hutchinson, D.V.M., the world’s leading animal stem cell practitioner. Dr. Hutchinson, who has spoken around the world about stem cell therapy, most recently in Tokyo, has performed more than 300 procedures over the last 18 months in his practice near Pittsburgh, PA.

Partnering with the leading animal health manufacturers in the world, Butler Schein maintains an order-fill ratio greater than 98 percent, and is positioned to bring the broadest selection of veterinary products and strategic business solutions to veterinarians, including:

    A comprehensive product offering for companion animal, equine and large animal practices including biologicals, diagnostics, nutritionals, parasiticides and pharmaceuticals

    Technology hardware and software solutions     Capital equipment, supply products and repair services     Practice design and remodeling, client marketing and financial solutions

Stem cells are basic biological cells with the ability to differentiate into specialized tissue cells and regenerate new cells to replace or repair damaged tissue. The stem cells used in veterinary medicine are not embryonic, which have attracted controversy over the years, but are taken from adipose (fat) tissue of the adult animal.

Americans spent an estimated $50.8 billion in 2011 on their companion animals, according to the American Pet Products Association, up from $28.5 billion in 2001. MediVet-America’s stem cell treatment costs about $1,800 for small animals, $2,400 for horses. Stem cells also can be frozen and banked for future use through MediVet Lab Services.

MEDIVET-AMERICA

A research and development company and global leader in veterinary stem cell technology, MediVet-America provides innovative cell applications for the therapeutic care of animals. Headquartered in Nicholasville, Kentucky, MediVet-America develops advanced cellular designed kits and services for the treatment of arthritis and degenerative joint disease. The company also offers MediVet Lab Services in multiple locations around the world that provides technical support for in-house stem cell vets, as well as regional and national Adipose stem cell processing and cryo banking services for pets at a young age or for a maintenance program, autologous conditioned serum processing, and cell counting for in-house stem cell procedures. http://www.MediVet-America.com

BUTLER SCHEIN ANIMAL HEALTH

Butler Schein Animal Health is the leading U.S. companion animal health distribution company. Headquartered in Dublin, Ohio, the company operates through 18 distribution centers and 12 telecenters. Approximately 900 Butler Schein Animal Health team members, including 300 field sales representatives and 200 telesales and customer support representatives, serve animal health customers in all 50 states. http://www.ButlerShein.com

###

Dick Roberts
Roberts Communications
(412) 535-5000
Email Information

Here is the original post:
MediVet-America Partners With Butler Schein Animal Health to Distribute World's Leading Animal Stem Cell Technology to ...

CAMBRIDGE, Mass., Feb. 21, 2012 (GLOBE NEWSWIRE) -- Pathfinder Cell Therapy, Inc. ("Pathfinder," or "the Company") (OTCQB:PFND.PK - News), a biotechnology company focused on the treatment of diabetes and other diseases characterized by organ-specific cell damage, today presented preliminary data highlighting the potential of the Company's unique cell-based therapy for treating diabetes at the 7th Annual New York Stem Cell Summit. Richard L. Franklin, M.D., Ph.D., Founder, CEO and President of Pathfinder, provided an overview of the Company's Pathfinder Cell ("PC") technology, and presented preclinical evidence demonstrating how treatment with PCs was able to reverse the symptoms of diabetes in two different mouse models.

Pathfinder Cells are a newly identified non-stem cell mammalian cell type that has the ability to stimulate regeneration of damaged tissue without being incorporated into the new tissue. In today's presentation, Dr. Franklin showed how recent experiments performed using a non-obese diabetic (NOD) mouse strain were supportive of earlier data that demonstrated complete reversal of diabetes in mice. The earlier results, which used a drug-induced diabetic mouse model, were published in Rejuvenation Research1. Though preliminary, the recent results are encouraging because the NOD mouse model is widely used and highly regarded as being predictive of human type-1 diabetes.

In three separate experiments using this model, 30-50% of the mice treated with PCs at the onset of diabetes returned to normal blood glucose levels. Of the mice that responded well to treatment, the effects tended to be long lasting, up to two months in some cases after just two doses. These results, which were generated by intravenous injection of PC's derived from rat pancreatic tissue, further demonstrate the remarkable ability of Pathfinder Cells to elicit their positive effect regardless of the organ, or even species, of origin.

"We are very encouraged by these preclinical results using NOD mice. This model is the gold standard for type-1 diabetes and the fact that recent experiments mirror what we've seen in previous models may be highly significant," stated Dr. Franklin. "We have many questions to answer about how PCs act in the body, but we believe, based on previous experiments, that PCs may stimulate regeneration of damaged islet cells that produce insulin. The current NOD mouse data also suggest that PCs may have an effect in modulating the auto-immune process in type 1 diabetes. We continue to conduct experiments aimed at elucidating the optimal dosing and other factors that may be responsible for producing a robust and long-lasting response, as this will be critical as we start to think about how PCs may be used in treating human diabetes."

In his presentation today, Dr. Franklin also provided further insight into the mechanism of action of PCs, based on recent animal experiments. It was observed previously that PCs produce microvesicles, which are known to play a role in intercellular communication, but through mechanisms that are poorly understood. In a recent experiment, Pathfinder was able to isolate these microvesicles from the PCs and treat animals directly with an injection containing microvesicles only. Remarkably, both PC- and microvesicle-treated mice exhibited similar reductions in blood glucose compared to controls using the same drug-induced diabetes mouse model. This suggests, not only that the microvesicles produced by PCs are central to the mechanism of action, but that the microvesicles alone appear to be sufficient to produce the full effect.

Dr. Franklin commented, "If confirmed, this finding could have a significant positive impact on the future of PC-based therapy. Due to the relatively small amount of material contained within the microvesicles, determining the specific factor(s) that are responsible for regenerating damaged tissue could be more straightforward than we first anticipated, bringing us closer to understanding the mechanism of action. There may also be a number of potential manufacturing and storage benefits to using microvesicles versus PCs that will be interesting to explore in parallel as we work to advance this innovative new therapeutic approach closer to human clinical development."

The New York Stem Cell Summit brings together cell therapy company executives, researchers, investors and physicians to explore investment opportunities in cell therapy research and innovation. More information can be found at http://www.stemcellsummit.com.

Presentation details Event: 7th Annual New York Stem Cell Summit Date: Tuesday, February 21, 2012 Place: Bridgewaters New York, 11 Fulton Street, New York, NY Time: 3:35 pm ET

About Pathfinder

Pathfinder is developing a novel cell-based therapy and has generated encouraging preclinical data in models of diabetes, renal disease, myocardial infarction, and critical limb ischemia, a severe form of peripheral vascular disease. Leveraging its internal discovery of Pathfinder Cells ("PCs") Pathfinder is pioneering a new field in regenerative medicine.

PCs are a newly identified mammalian cell type present in very low quantities in a variety of organs, including the kidney, liver, pancreas, lymph nodes, myometrium, bone marrow and blood. Early studies indicate that PCs stimulate regeneration of damaged tissues without the cells themselves being incorporated into the newly generated tissue. Based on testing to date, the cells appear to be "immune privileged," and their effects appear to be independent of the tissue source of PCs. For more information please visit: http://www.pathfindercelltherapy.com.

FORWARD LOOKING STATEMENTS

This press release contains forward-looking statements. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our inability to obtain additional required financing; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results, if any; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; technological changes; and government regulation. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

1Karen Stevenson, Daxin Chen, Alan MacIntyre, Liane M McGlynn, Paul Montague, Rawiya Charif, Murali Subramaniam, W.D. George, Anthony P. Payne, R. Wayne Davies, Anthony Dorling, and Paul G. Shiels. Rejuvenation Research. April 2011, 14(2): 163-171. doi:10.1089/rej.2010.1099

Read the original post:
Pathfinder Presents Preliminary Data on New Regenerative Approach to Diabetes Treatment